M&T Bank Corp Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

M&T Bank Corp cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,912 shares of the medical equipment provider’s stock after selling 2,845 shares during the period. M&T Bank Corp’s holdings in Lantheus were worth $284,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Summit Securities Group LLC purchased a new stake in shares of Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. boosted its stake in Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock valued at $92,000 after acquiring an additional 381 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Lantheus by 117.7% in the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 633 shares during the last quarter. GAMMA Investing LLC raised its holdings in Lantheus by 29.3% during the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock worth $128,000 after purchasing an additional 298 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Lantheus during the 4th quarter worth approximately $125,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research note on Wednesday. Finally, B. Riley cut their price target on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a report on Monday, June 23rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $131.20.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

Lantheus Stock Down 1.1%

Lantheus stock opened at $73.60 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The firm has a market capitalization of $5.09 billion, a price-to-earnings ratio of 20.91 and a beta of 0.12. The company’s 50 day simple moving average is $79.04 and its 200 day simple moving average is $89.57. Lantheus Holdings, Inc. has a fifty-two week low of $69.12 and a fifty-two week high of $122.83.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter last year, the business earned $1.69 earnings per share. Lantheus’s revenue for the quarter was up .8% on a year-over-year basis. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.